Prophylaxis for patients at Risk to Eliminate Post-operative Atrial Fibrillation (PREP-AF trial): a protocol for a feasibility randomized controlled study
Open Access
- 7 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 22 (1), 1-10
- https://doi.org/10.1186/s13063-021-05318-1
Abstract
Postoperative atrial fibrillation (POAF) is a frequent adverse event after thoracic surgery with associated morbidity, mortality, and healthcare costs. It has been shown to be preventable with prophylactic amiodarone, which is only recommended in high-risk individuals due to the potential associated side effects. Risk factors for POAF have been identified and incorporated into a prediction model to identify high-risk patients. Further evaluation in the form of a multicenter clinical trial is required to assess the effectiveness of prophylaxis specifically in this high-risk population. The feasibility of such a trial first needs to be assessed. The PREP-AF trial is a double-blind randomized controlled feasibility trial. Individuals undergoing major thoracic surgery who are identified to be high-risk by the POAF prediction model will be randomized 1:1 to receive a short course of amiodarone vs. placebo in the immediate postoperative period. The primary outcome is feasibility, which will be measured by the number of eligible patients identified, consented, and randomized; intervention adherence; and measurement of future outcomes of a full trial. This study will determine the feasibility of a randomized controlled trial to assess the effectiveness of prophylactic amiodarone, in high-risk patients undergoing major thoracic surgery. This will inform the development of a multi-center trial to establish if prophylactic amiodarone is safe and effective at reducing the incidence of POAF. Preventing this adverse event will not only improve outcomes for patients but also reduce the associated health resource utilization and costs. ClinicalTrials.gov NCT04392921. Registered on 19 May 2020.Funding Information
- The Ottawa Hospital Academic Medicine Organization (TOH -21 -014)
This publication has 23 references indexed in Scilit:
- A review and analysis of strategies for prediction, prevention and management of post-operative atrial fibrillation after non-cardiac thoracic surgeryJournal of Thoracic Disease, 2018
- Drug-Induced QT Prolongation And Torsades de Pointes.2017
- Drug-induced QT interval prolongation and torsades de pointesCanadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2016
- 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical proceduresThe Journal of Thoracic and Cardiovascular Surgery, 2014
- Amiodarone Significantly Decreases Atrial Fibrillation in Patients Undergoing Surgery for Lung CancerThe Annals of Thoracic Surgery, 2012
- Systematic Classification of Morbidity and Mortality After Thoracic SurgeryThe Annals of Thoracic Surgery, 2010
- Risk Factors for Atrial Fibrillation After Lung Cancer Surgery: Analysis of The Society of Thoracic Surgeons General Thoracic Surgery DatabaseThe Annals of Thoracic Surgery, 2010
- A randomized, controlled study of amiodarone for prevention of atrial fibrillation after transthoracic esophagectomyThe Journal of Thoracic and Cardiovascular Surgery, 2010
- Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmiasEP Europace, 2007
- QT prolongation and the antiarrhythmic efficacy of amiodaroneJournal of Invasive Cardiology, 1986